ArticleAnnals of hematology2025
Characterization and risk assessment of HbF elevation in non-thalassemia hematologic disease patients in Guangdong region.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study analyzed clinical data and hematological parameters from 3072 patients undergoing thalassemia screening at Guangdong Provincial People's Hospital, investigating the correlation between non-thalassemic hematologic diseases and elevated fetal hemoglobin (HbF) in Guangdong. Results revealed a significant correlation and identified non-thalassemic hematologic diseases as an independent risk factor for HbF elevation (OR = 13.36, P < 0.001), indicating a substantially higher risk than that of non-hematologic disease patients. Among patients with elevated HbF, significant parameter differences emerged: non-thalassemia hematologic disease patients differed from mild β-thalassemia patients with elevated HbF in mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), red cell distribution width-coefficient of variation (RDW-CV) (P < 0.05); Significant differences in MCV, MCH, RDW-CV, creatinine (CREA), ferritin (Ferr), total bilirubin (TBIL) and direct bilirubin (DBIL) were found between patients with non-thalassemic hematologic diseases and moderate-to-severe β-thalassemia with elevated HbF levels (P < 0.05). Furthermore, significant differences existed between mild and moderate-to-severe β-thalassemia patients with elevated HbF in MCV, MCH, Ferr, TBIL and DBIL (P < 0.05). This research delineates the epidemiological characteristics of hematologic disease-associated HbF elevation in Guangdong, addressing a regional knowledge gap and providing a foundation for clinical risk stratification. Analysis of these differential hematologic indicators deepens understanding of non-thalassemia disease progression, offers clinicians targeted diagnostic and therapeutic strategies, facilitates early detection and intervention, and contributes to broader hematologic research and discipline development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.